apmsolutions

Biomanufacturing optimization is often slow, complex, and resource-intensive. Virica is excited to introduce Viric.AI™, a proprietary active learning platform that expands Virica’s capabilities with a smarter, faster approach to biomanufacturing optimization. Developed in collaboration with Dr. Francesco Gentile’s lab at the University of Ottawa, Viric.AI™ combines machine learning with iterative experimental feedback to help guide [...]

AAV manufacturing remains a major bottleneck in gene therapy, limiting scalability, increasing production challenges, and slowing the path to broader patient access.  Virica is pleased to announce its selection under the NRC IRAP Canada–Japan Corporate Co-Innovation Program for a collaboration with FUJIFILM Biosciences. The project will focus on developing an off-the-shelf enhancer–media solution to improve AAV yield and process robustness in the FUJIFILM Biosciences BalanCD® HEK293 system.  The [...]

Virica Biotech and eXmoor Pharma have announce a new collaboration project funded by a joint UK-Canada government initiative.  This project aims to enhance the manufacturing of adeno-associated vectors (AAVs) crucial for gene therapies, ultimately reducing costs and improving the accessibility of life-saving therapies.  The collaborative project will utilize Virica’s VSEs™, small molecules that have been [...]

Wednesday November 20th,  08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET Virica Biotech and Culture Biosciences will present innovative solutions to address the high costs associated with gene therapy manufacturing. Real-world case studies will highlight improved productivity, shorter timelines, and more efficient scale-up. Attendees will gain insights into optimizing AAV production using [...]

Virica Biotech and Ginkgo Bioworks have announced a strategic partnership aimed at improving AAV gene therapy production. Virica will provide a panel of its Viral Sensitizer Enhancers (VSETM) to Ginkgo for high-throughput AAV production screening, while Ginkgo will utilize its advanced screening platform to test VSEs directly in clients' cell lines. This collaboration is expected [...]

OTTAWA – October 4, 2021 – Virica Biotech Inc., a leading life science developer of solutions for scaling of viral medicines, announced today the first closing of its Series A financing. The round, led by Dynamk Capital, is expected to close with additional investors by the end of Q4-2021. The investment strengthens Virica’s already impressive growth trajectory, [...]